Cargando…

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

BACKGROUND: AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain. METHODS: Post...

Descripción completa

Detalles Bibliográficos
Autores principales:	Provencio, Mariano, Terrasa, Josefa, Garrido, Pilar, Campelo, Rosario García, Aparisi, Francisco, Diz, Pilar, Aguiar, David, García-Giron, Carlos, Hidalgo, Julia, Aguado, Carlos, González, Jorge García, Esteban, Emilio, Gómez-Aldavarí, Lorenzo, Moran, Teresa, Juan, Oscar, Chara, Luís Enrique, Marti, Juan L., Castro, Rafael López, Ortega, Ana Laura, Moreno, Elia Martínez, Coves, Juan, Sánchez Peña, Ana M., Bosch-Barrera, Joaquim, Gastaldo, Amparo Sánchez, Núñez, Natalia Fernández, del Barco, Edel, Cobo, Manuel, Isla, Dolores, Majem, Margarita, Navarro, Fátima, Calvo, Virginia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937205/ https://www.ncbi.nlm.nih.gov/pubmed/33676426 http://dx.doi.org/10.1186/s12885-021-07922-5

Ejemplares similares

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
por: Viñolas, N. Nuria, et al.
Publicado: (2020)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
por: Isla, D., et al.
Publicado: (2020)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
por: Majem, M., et al.
Publicado: (2018)

Are there differences by sex in lung cancer characteristics at diagnosis? —a nationwide study
por: Ruano-Ravina, Alberto, et al.
Publicado: (2021)

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program
por: Bernabé-Caro, Reyes, et al.
Publicado: (2022)

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
por: Provencio, Mariano, et al.
Publicado: (2022)

Lung cancer patients with COVID-19 in Spain: GRAVID study
por: Provencio, Mariano, et al.
Publicado: (2021)

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
por: Arriola, Edurne, et al.
Publicado: (2018)

Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
por: Suay, Guillermo, et al.
Publicado: (2023)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
por: Garrido, Pilar, et al.
Publicado: (2021)

Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department
por: Sánchez, Juan C., et al.
Publicado: (2023)

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
por: Provencio, Mariano, et al.
Publicado: (2022)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
por: García-Campelo, R., et al.
Publicado: (2015)

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
por: Gutiérrez, Lourdes, et al.
Publicado: (2021)

Identifying high-risk individuals for lung cancer screening: Going beyond NLST criteria
por: Fu, Marcela, et al.
Publicado: (2018)

Lung cancer symptoms at diagnosis: results of a nationwide registry study
por: Ruano-Raviña, Alberto, et al.
Publicado: (2020)

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2018)

A Decentralized Wireless Solution to Monitor and Diagnose PV Solar Module Performance Based on Symmetrized-Shifted Gompertz Functions
por: Molina-García, Angel, et al.
Publicado: (2015)

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2019)

A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
por: Isla, Dolores, et al.
Publicado: (2022)

Accumulation of Scandium in Plasma in Patients with Chronic Renal Failure
por: Sánchez-González, Cristina, et al.
Publicado: (2013)

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
por: Rosell, Rafael, et al.
Publicado: (2009)

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
por: Romero, Atocha, et al.
Publicado: (2020)

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
por: Martínez-García, María, et al.
Publicado: (2022)

Low-level predation by lytic phage phiIPLA-RODI promotes biofilm formation and triggers the stringent response in Staphylococcus aureus
por: Fernández, Lucía, et al.
Publicado: (2017)

Analysis of Different Parameters Affecting Diffusion, Propagation and Survival of Staphylophages in Bacterial Biofilms
por: González, Silvia, et al.
Publicado: (2018)

Insight into the Lytic Functions of the Lactococcal Prophage TP712
por: Escobedo, Susana, et al.
Publicado: (2019)

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
por: Zang, Shu-Zhi, et al.
Publicado: (2017)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

Parámetros productivos y reproductivos de ganado Holstein-Friesian puro en el trópico /
por: García Sánchez, Juan Carlos
Publicado: (1988)

Alveolar Overdistension as a Cause of Lung Injury: Differences among Three Animal Species
por: García-Delgado, Manuel, et al.
Publicado: (2012)

The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
por: Conde, Esther, et al.
Publicado: (2010)

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
por: Provencio, Mariano, et al.
Publicado: (2023)

Severe Hyponatremia Masking Central Diabetes Insipidus in a Patient with a Lung Adenocarcinoma
por: Terán Brage, Eduardo, et al.
Publicado: (2022)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Targeting KRAS in Non-Small Cell Lung Cancer
por: Corral de la Fuente, Elena, et al.
Publicado: (2022)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hn4pdh3a6b510um531ssd63qd9